End-of-day quote
NSE India S.E.
23:00:00 08/05/2024 BST
|
5-day change
|
1st Jan Change
|
833.4
INR
|
-0.84%
|
|
-0.93%
|
+26.83%
|
Fiscal Period: March |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
56,215
|
48,141
|
101,422
|
-
|
-
|
Enterprise Value (EV)
1 |
51,123
|
45,047
|
95,161
|
101,422
|
101,422
|
P/E ratio
|
12.9
x
|
10.3
x
|
20.2
x
|
18.4
x
|
16.1
x
|
Yield
|
2.29%
|
5.34%
|
2.55%
|
2.91%
|
3.03%
|
Capitalization / Revenue
|
2.63
x
|
2.23
x
|
4.17
x
|
3.93
x
|
3.43
x
|
EV / Revenue
|
2.39
x
|
2.08
x
|
4.17
x
|
3.93
x
|
3.43
x
|
EV / EBITDA
|
8.1
x
|
7.01
x
|
14.1
x
|
12.9
x
|
11.1
x
|
EV / FCF
|
11.3
x
|
31.5
x
|
32
x
|
47.7
x
|
40.2
x
|
FCF Yield
|
8.85%
|
3.18%
|
3.12%
|
2.1%
|
2.49%
|
Price to Book
|
-
|
2.25
x
|
4.09
x
|
3.6
x
|
3.08
x
|
Nbr of stocks (in thousands)
|
122,527
|
122,527
|
122,527
|
-
|
-
|
Reference price
2 |
458.8
|
392.9
|
827.8
|
827.8
|
827.8
|
Announcement Date
|
20/04/22
|
27/04/23
|
25/04/24
|
-
|
-
|
Fiscal Period: March |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
18,852
|
21,379
|
21,612
|
22,832
|
25,787
|
29,542
|
EBITDA
1 |
-
|
6,308
|
6,423
|
6,742
|
7,887
|
9,120
|
EBIT
1 |
-
|
5,929
|
6,002
|
6,208
|
7,339
|
8,414
|
Operating Margin
|
-
|
27.73%
|
27.77%
|
27.19%
|
28.46%
|
28.48%
|
Earnings before Tax (EBT)
1 |
-
|
5,649
|
6,286
|
6,313
|
7,517
|
8,489
|
Net income
1 |
-
|
4,187
|
4,670
|
4,709
|
5,504
|
6,307
|
Net margin
|
-
|
19.59%
|
21.61%
|
20.62%
|
21.35%
|
21.35%
|
EPS
2 |
-
|
35.63
|
38.11
|
38.38
|
44.87
|
51.41
|
Free Cash Flow
1 |
-
|
4,524
|
1,432
|
3,056
|
2,127
|
2,525
|
FCF margin
|
-
|
21.16%
|
6.63%
|
12.78%
|
8.25%
|
8.55%
|
FCF Conversion (EBITDA)
|
-
|
71.73%
|
22.3%
|
41.56%
|
26.97%
|
27.69%
|
FCF Conversion (Net income)
|
-
|
108.05%
|
30.67%
|
58.63%
|
38.64%
|
40.04%
|
Dividend per Share
2 |
-
|
10.50
|
21.00
|
21.10
|
24.07
|
25.07
|
Announcement Date
|
20/07/21
|
20/04/22
|
27/04/23
|
25/04/24
|
-
|
-
|
Fiscal Period: March |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
5,638
|
5,260
|
5,192
|
4,994
|
5,093
|
5,407
|
6,213
|
5,784
|
5,980
|
6,025
|
6,070
|
EBITDA
1 |
-
|
1,496
|
-
|
1,468
|
1,436
|
1,455
|
2,064
|
1,932
|
2,012
|
1,693
|
1,702
|
EBIT
1 |
1,598
|
1,399
|
1,378
|
1,464
|
1,437
|
1,413
|
1,949
|
1,824
|
1,947
|
-
|
1,708
|
Operating Margin
|
28.33%
|
26.59%
|
26.53%
|
29.31%
|
28.22%
|
26.13%
|
31.37%
|
31.53%
|
32.56%
|
-
|
28.14%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1,820
|
-
|
-
|
1,729
|
Net income
1 |
-
|
1,037
|
-
|
1,087
|
1,069
|
1,050
|
1,464
|
1,354
|
1,419
|
1,182
|
1,176
|
Net margin
|
-
|
19.72%
|
-
|
21.77%
|
20.99%
|
19.42%
|
23.56%
|
23.42%
|
23.73%
|
19.62%
|
19.36%
|
EPS
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
11.05
|
-
|
-
|
10.40
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/21
|
08/02/22
|
20/04/22
|
04/08/22
|
21/10/22
|
27/01/23
|
27/04/23
|
21/07/23
|
-
|
-
|
-
|
Fiscal Period: March |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
5,093
|
3,094
|
3,498
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
4,524
|
1,432
|
3,056
|
2,127
|
2,525
|
ROE (net income / shareholders' equity)
|
-
|
29.8%
|
22.3%
|
22.7%
|
21.9%
|
21.9%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
175.0
|
202.0
|
230.0
|
269.0
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1,452
|
1,702
|
1,606
|
3,333
|
2,833
|
Capex / Sales
|
-
|
6.79%
|
7.87%
|
6.72%
|
12.93%
|
9.59%
|
Announcement Date
|
20/07/21
|
20/04/22
|
27/04/23
|
25/04/24
|
-
|
-
|
Last Close Price
827.8
INR Average target price
905.8
INR Spread / Average Target +9.42% Consensus |
1st Jan change
|
Capi.
|
---|
| +26.83% | 1.21B | | +30.38% | 684B | | +26.51% | 568B | | -4.36% | 361B | | +19.30% | 329B | | +3.73% | 284B | | +16.70% | 240B | | +8.78% | 208B | | -7.93% | 200B | | +7.68% | 166B |
Other Pharmaceuticals
|